识别处方级联潜在药物对的文本挖掘算法:PINA数字工具开发与内部验证
处方级联指药物不良反应被额外药物处理,可能加重不适当多重用药。本研究在PINA数字工具中开发基于意大利SmPC与MedDRA的文本挖掘算法,识别潜在处方级联药物对,并以69个文献支持阳性对和138个随机阴性对验证。联合HLT/SMQ扩展模型表现最佳,准确率94.7%,PPV 98.3%,NPV 93.2%。
要点
- 算法通过匹配ADR与治疗适应症的MedDRA术语交集识别潜在处方级联。
- PT联合HLT/SMQ扩展模型敏感性85.5%、特异性≥99%、准确率94.7%。
- 该MedDRA驱动方法可支持结构化用药审查,辅助识别潜在处方级联。
核心结论
- 新算法分类性能高,尤其将PT级匹配扩展至HLT和SMQ时表现最佳。
- 基于监管数据的MedDRA驱动方法可能成为支持结构化用药审查的可扩展且可重复策略。
研究设计与样本
- 算法作为PINA数字工具组件开发,通过自然语言处理管道从意大利SmPC提取ADR与治疗适应症并编码为MedDRA术语。
- 测试四种MedDRA语义层级匹配配置:仅PT、PT+HLT、PT+SMQ、PT+HLT/SMQ。
- 以69个文献支持阳性药物对和138个随机生成阴性药物对(1:2比例)为参考标准进行内部验证。
主要发现
- 所有模型特异性≥99%。
- 敏感性:仅PT匹配50.7%,PT+HLT 73.9%,PT+SMQ 68.1%,PT+HLT/SMQ 85.5%。
- PT+HLT/SMQ联合扩展模型准确率94.7%、PPV 98.3%、NPV 93.2%、F1分数91.4、Youden指数84.8。
- 所有模型假阳性率保持极低。
关键数值与推荐
- 参考标准包含69个文献支持阳性药物对与138个随机阴性药物对,比例1:2。
- 性能指标包括敏感性、特异性、PPV、NPV、准确率、F1分数和Youden指数。
临床怎么用
- 该算法可作为PINA数字工具组件,在用药审查中辅助识别潜在处方级联药物对。
- 优先采用PT联合HLT/SMQ扩展配置以获得更高敏感性,同时保持高特异性。
局限性
- 研究为内部验证,未进行外部验证。
- 算法基于意大利SmPC和MedDRA术语,向其他监管数据体系推广需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prescribing cascades (PCs) occur when an adverse drug reaction (ADR) is intentionally or unintentionally treated with an additional medication, potentially perpetuating inappropriate polypharmacy. Digital tools that systematically support the identification of potential PCs during medication review are lacking. Here, we describe the development of an algorithm designed to identify drug pairs potentially compatible with PCs and evaluate its classification performance. METHODS: The algorithm was developed as a component of the Prescribing INappropriateness Assessment (PINA) digital tool, a software platform designed to support clinicians in conducting medication reviews. The algorithm logic identifies potential PCs by detecting intersections between ADRs and therapeutic indications extracted from Italian Summaries of Product Characteristics (SmPCs) and encoded as Medical Dictionary for Regulatory Activities (MedDRA) terms using a natural language processing pipeline. Four algorithm configurations were tested, differing in the MedDRA semantic levels used for matching: (1) Preferred Terms (PTs) only; (2) PTs with semantic extension to High Level Terms (HLTs); (3) PTs with extension to Standardised MedDRA Queries (SMQs); and (4) PTs with combined HLT/SMQ extension. Performance was assessed against a reference standard comprising 69 literature-supported positive drug pairs and 138 randomly generated negative drug pairs in a 1:2 ratio. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, F1 score, and Youden's index were calculated. RESULTS: All models demonstrated excellent specificity (≥ 99%). Sensitivity increased with semantic expansion: 50.7% for PT-only matching, 73.9% for PT+HLT, 68.1% for PT+SMQ, and 85.5% for PT+HLT/SMQ. The combined HLT/SMQ extension model achieved the highest overall performance, with an accuracy of 94.7%, a PPV of 98.3%, an NPV of 93.2%, an F1 score of 91.4, and a Youden's index of 84.8. False-positive rates remained minimal across all models. CONCLUSIONS: The newly developed algorithm demonstrated high classification performance, particularly when PT-level matching was extended using both HLTs and SMQs. This MedDRA-driven approach based on regulatory data may represent a scalable and reproducible strategy for supporting structured medication review and facilitating the recognition and clinical evaluation of potential PCs.
引用
- Carollo M, Forti A, Crisafulli S, et al. A Text-Mining Algorithm for Identifying Drug Pairs Potentially Involved in Prescribing Cascades: Development and Internal Validation Within the Prescribing Inappropriateness Assessment (PINA) Digital Tool. Drug Saf. 2026. PMID: 42763348. doi:10.1007/s40264-026-01733-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。